Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02750982|
Recruitment Status : Recruiting
First Posted : April 26, 2016
Last Update Posted : January 23, 2018
|Condition or disease||Intervention/treatment|
|Alzheimer's Disease Amyotrophic Lateral Sclerosis Brain Injury Huntington's Disease Multiple Sclerosis Parkinson's Disease Stroke Spinal Cord Injury||Other: Laughter Therapy|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||A Single-Arm Prospective Investigation of the Effects of Laughter Therapy on Mood, Stress, and Self-Efficacy in People With Central Nervous System Disorders.|
|Study Start Date :||July 2016|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: Laughter therapy
effects of Laughter therapy (LT) on mood, self-efficacy and other wellness measures in people with neurological conditions.
Other: Laughter Therapy
Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
- Patient Health Questionnaire (PHQ-9, for depression) [ Time Frame: Change from Baseline to 8 weeks ]Outcome measures will be completed at baseline, active-phase completion at week 8 and post-active phase week 8 (16 weeks post-start of active phase).
- Generalized Anxiety Disorder 7-item scale (GAD-7, for anxiety) [ Time Frame: Change from Baseline to 8 weeks ]Outcome measures will be completed at baseline, active-phase completion at week 8 and post-active phase week 8 (16 weeks post-start of active phase).
- The General Self-Efficacy Scale (GSE) [ Time Frame: Change from Baseline to 8 weeks ]Outcome measures will be completed at baseline, active-phase completion at week 8 and post-active phase week 8 (16 weeks post-start of active phase).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02750982
|Contact: Canan Akture, CRCemail@example.com|
|Contact: Carey Gonzales, CRCfirstname.lastname@example.org|
|United States, Washington|
|Kirkland, Washington, United States, 98034|
|Contact: Canan Akture, Research Coordinator 425-899-5393 email@example.com|
|Contact: Carey Gonzales, Research Coordinator 425-899-5374 firstname.lastname@example.org|
|Principal Investigator: Theodore R Brown, MD, MPH|
|Principal Investigator:||Theodore R Brown, MD, MPH||Evergreen Healthcare|